Sidebar: Biologics In The Spotlight: J&J’s Ustekinumab & Golimumab
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Both J&J-sponsored MAbs on the 2009 calendar, ustekinumab and Simponi (golimumab), are looking to break into established biologic markets (psoriasis, rheumatoid arthritis) with products that have a significant dosing advantage over approved biologics.